An international, multicentre, interventional, randomised, assessor-blinded trial to MAXimise the METHotrexate therapy potential in patients with active rheumatoid arthritis (MethMax trial): study protocol for a randomised controlled trial
The anticipated results will provide insights whether the subcutaneous administration of 25 mg MTX is advantageous in achieving CDAI remission when compared to the oral intake after 24 weeks and inform the community regarding the utility of established and newly developed biomarkers, as well as the potential impact of inadequate drug adherence. The MethMax study is aimed to optimise individual therapy in RA and provide more precise pharmacological MTX management recommendations.
Authors
- Martina Durechova
- C Popescu (ORCID: https://orcid.org/0000-0002-8236-1242)
- Eirik Klami Kristianslund (ORCID: https://orcid.org/0000-0002-4963-3285)
- Souzi Makri
- Daniela Sieghart (ORCID: https://orcid.org/0000-0003-1281-2295)
- Siri Lillegraven (ORCID: https://orcid.org/0000-0003-3615-0134)
- Helga Lechner-Radner
- Karolina Anderle
- Andreas Kerschbaumer (ORCID: https://orcid.org/0000-0002-6685-8873)
- Sabina De Geest (ORCID: https://orcid.org/0000-0001-6596-7237)
- Elisa Gremese (ORCID: https://orcid.org/0000-0002-2248-1058)
- F. Bonnay
- Agnes Kocher
- Espen A. Haavardsholm
- Katerina Chatzidionysiou
- Costantino Pitzalis
- Catalin Codreanu
- Rachel Knevel
- Daniel Aletaha
Institutions
- Karolinska University Hospital (SE)
- Humanitas University (IT)
- Carol Davila University of Medicine and Pharmacy (RO)
- Queen Mary University of London (GB)
- University of Oslo (NO)
- University of Basel (CH)
- Barts Health NHS Trust (GB)
- Leiden University Medical Center (NL)
- Karolinska Institutet (SE)
- Diakonhjemmet Hospital (NO)
- IRCCS Humanitas Research Hospital (IT)
- Medical University of Vienna (AT)
- National Patient Safety Foundation (US)
Publication Details
- Journal
- Trials
- Published
- 2026-03-23
- DOI
- https://doi.org/10.1186/s13063-026-09519-4
- Primary Topic
- Rheumatoid Arthritis Research and Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00